Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Ward SE, Eddershaw P, Flynn ST, Gordon L, Lovell PJ, Moore SH, Scott CM, Smith PW, Thewlis KM, Wyman PA. Studies on a series of potent, orally bioavailable, 5-HT1 receptor ligands—Part II. Bioorg Med Chem Lett 2009;19:428-32. [DOI: 10.1016/j.bmcl.2008.11.052] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2008] [Revised: 11/13/2008] [Accepted: 11/14/2008] [Indexed: 11/29/2022]

For:	Ward SE, Eddershaw P, Flynn ST, Gordon L, Lovell PJ, Moore SH, Scott CM, Smith PW, Thewlis KM, Wyman PA. Studies on a series of potent, orally bioavailable, 5-HT1 receptor ligands—Part II. Bioorg Med Chem Lett 2009;19:428-32. [DOI: 10.1016/j.bmcl.2008.11.052] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2008] [Revised: 11/13/2008] [Accepted: 11/14/2008] [Indexed: 11/29/2022]

Number

Cited by Other Article(s)

Cézard C, Bouvier B, Dassonville-Klimpt A, Sonnet P. The origin of the stereoselective alkylation of 3-substituted-2-oxopiperazines: A computational investigation. COMPUT THEOR CHEM 2016. [DOI: 10.1016/j.comptc.2015.12.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]

St Jean DJ, Fotsch C. Mitigating heterocycle metabolism in drug discovery. J Med Chem 2012;55:6002-20. [PMID: 22533875 DOI: 10.1021/jm300343m] [Citation(s) in RCA: 159] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]

Leslie CP, Biagetti M, Bison S, Bromidge SM, Di Fabio R, Donati D, Falchi A, Garnier MJ, Jaxa-Chamiec A, Manchee G, Merlo G, Pizzi DA, Stasi LP, Tibasco J, Vong A, Ward SE, Zonzini L. Discovery of 1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, Selective, and Orally Active 5-HT1A/B/D Receptor Antagonist. J Med Chem 2010;53:8228-40. [DOI: 10.1021/jm100714c] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]

Affiliation(s)

Colin P. Leslie Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
Matteo Biagetti Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
Silvia Bison Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
Steven M. Bromidge Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, United Kingdom
Romano Di Fabio Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
Daniele Donati Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
Alessandro Falchi Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
Martine J. Garnier Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
Albert Jaxa-Chamiec Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
Gary Manchee Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
Giancarlo Merlo Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
Domenica A. Pizzi Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
Luigi P. Stasi Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
Jessica Tibasco Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy
Antonio Vong Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, United Kingdom
Simon E. Ward Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, United Kingdom
Laura Zonzini Neurosciences Centre of Excellence for Drug Discovery, GlaxoSmithKline SpA, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy

Collapse

De Risi C, Pelà M, Pollini GP, Trapella C, Zanirato V. Mastering chiral substituted 2-oxopiperazines. ACTA ACUST UNITED AC 2010. [DOI: 10.1016/j.tetasy.2010.02.008] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]